<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210379</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG10</org_study_id>
    <nct_id>NCT00210379</nct_id>
  </id_info>
  <brief_title>Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <brief_summary>
    <textblock>
      The primary objective assess the clinical activity of combination doxorubicin-containing
      chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic
      chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to
      assess the toxicity of this therapeutic strategy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival will be a secondary end-point because post-relapse therapy is not specified in this protocol and is expected to be highly variable</measure>
  </secondary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Lymphoma, B Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age = 18 years.

          2. ECOG performance status 0-2

          3. Histologically proven primary testicular CD20-positive diffuse large B-cell
             non-Hodgkin's lymphoma, untreated

          4. Ann Arbor stage IE or IIE. Bilateral testicular involvement at presentation will not
             be considered stage IV. In these patients the final Ann Arbor stage will be determined
             by the extent of nodal involvement.

          5. Bidimensionally measurable or evaluable disease. Patients who have had all disease
             removed by surgery are eligible.

          6. Adequate bone marrow reserve (ANC &gt; 1.000/L, Plt &gt; 100.000/L)

          7. Cardiac ejection fraction â‰¥ 50% by MUGA scan or echocardiography

          8. No previous therapy with monoclonal antibody anti-CD20.

          9. No psychiatric illness that precludes understanding concepts of the trial or signing
             informed consent

         10. No other major life-threatening illnesses that may preclude chemotherapy

         11. Have given written informed consent prior to any program-specific screening procedure,
             with the understanding that the consent may be withdrawn by the patient at any time
             without prejudice

        Exclusion Criteria:

          1. impairment of renal function (creatinine &gt; 2 mg/dl) or liver function (bilirubin &gt; 2
             mg/dl) unless due to lymphoma involvement

          2. HIV positive patients

          3. evolutive malignancy within 5 years with the exception of localized non-melanomatous
             skin cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Sarris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Extranodal Lymphoma Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland (IOSI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Gospodarowicz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiation Oncology. Princess Margareth Hospital. Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hematology Division. Ospedale San Giovanni Battista. Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ielsg.org</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 21, 2009</last_update_submitted>
  <last_update_submitted_qc>July 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>International Extranodal Lymphoma Study Group (IELSG)</name_title>
    <organization>IELSG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

